Nuvation Bio Inc. NUVB
Set alert
4.76 USD -0.01 -0.21%
At close · Oct 30
4.74 -0.02 -0.42%
After hours · Oct 30, 5:39 PM ET
4.60 Day range 4.81
4.05 52-week range 9.54
- YTD
- -46.88%
- 1 year
- -7.57%
- Open
- 4.75
- Prev close
- 4.77
- Mkt cap
- 1.67B
- Vol
- 5.06M
- Avg vol
- 5.35M
- EPS
- -0.44
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.60
- High
- 4.81
- Forward P/E
- -317.00
- Beta
- 1.62
- Short ratio
- 11.57
- Inst. own
- 67.84%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 5.68
- 200-d avg
- 5.41
- 1y target
- 13.00
6M chart
Events in this range
- May 4, 2026Earnings: 0.01; estimate -0.02804; surprise 135.66%
- Aug 6, 2026Earnings: -0.15; estimate -0.14166; surprise -5.89%
- Aug 7, 2026Rating: RBC Capital · Outperform → Outperform
- Aug 18, 2026Rating: JP Morgan · — → Overweight
- Aug 21, 2026Rating: Cantor Fitzgerald · — → Overweight
- Sep 16, 2026Rating: Wedbush · Outperform → Outperform
- Sep 16, 2026Rating: Citizens · Market Outperform → Market Outperform
- Sep 30, 2026Rating: Citigroup · — → Buy
Signals (25)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| RSI: Oversold | Oct 12, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 19, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 3, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 21, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 10, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 9, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 2, 2026 | 4 months ago |
| RSI: Overbought | Jun 23, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 12, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | Jun 10, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 10, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 4 months ago |
| SMA: Bullish | Jun 4, 2026 | 5 months ago |
| MACD: Buy Signal | May 26, 2026 | 5 months ago |
| SMA: Bullish | May 21, 2026 | 5 months ago |
| SMA: Bearish | May 15, 2026 | 5 months ago |
| MACD: Sell Signal | May 15, 2026 | 5 months ago |
| MACD: Buy Signal | May 6, 2026 | 5 months ago |
| SMA: Bullish | May 5, 2026 | 6 months ago |
Key statistics
- Market cap
- 1.67B
- Enterprise value
- 1.43B
- Trailing P/E
- 0.00
- Forward P/E
- -317.00
- PEG ratio
- 0.00
- Price / sales
- 9.83
- Price / book
- 6.55
- EPS (TTM)
- -0.44
- Beta
- 1.62
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -88.19%
- Revenue (TTM)
- 169.90M
- Revenue growth
- 555.60%
- Free cash flow
- -112.11M
- Total cash
- 660.96M
- Total debt
- 416.26M
- Return on equity
- -47.81%
- Shares outstanding
- 350.12M
- Short % of float
- 29.65%
- 50-day average
- 5.68
- 200-day average
- 5.41
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 13.00 +173.1% upside
Now 4.76
- Target (low)
- 7.00
- Target (mean)
- 13.00
- Target (high)
- 21.00
Ratings (0m) 13 12 buy · 1 hold · 0 sell
- Strong buy3
- Buy9
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate -0.10333.
Financials — quick view
NUVB Revenue — quarterly 31.69M
NUVB Net income — quarterly -62.84M
NUVB EPS — quarterly -0.18
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -0.12357 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.14166 | -0.15 | -0.01 | -5.89% |
| May 4, 2026 | Mar 31, 2026 | -0.02804 | 0.01 | +0.04 | +135.66% |
| Mar 2, 2026 | Dec 31, 2025 | -0.11 | -0.11 | 0.00 | 0.00% |
| Nov 3, 2025 | Sep 30, 2025 | -0.17 | -0.16 | +0.01 | +5.88% |
| Aug 7, 2025 | Jun 30, 2025 | -0.17 | -0.17 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 30, 2026 | Citigroup | init | — | Buy |
| Sep 16, 2026 | Citizens | reit | Market Outperform | Market Outperform |
| Sep 16, 2026 | Wedbush | reit | Outperform | Outperform |
| Aug 21, 2026 | Cantor Fitzgerald | init | — | Overweight |
| Aug 18, 2026 | JP Morgan | init | — | Overweight |
| Aug 7, 2026 | RBC Capital | main | Outperform | Outperform |
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nuvationbio.com
News
- Nuvation Bio Plans To Add Sites In Six European Countries For Its Pivotal Phase 3 SIGMA Study Of Safusidenib
- Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries
- Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026
- This Ciena Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
- Nuvation Bio Inc. (NYSE:NUVB) Stock Rated “Moderate Buy” by Wall Street Analysts
- Citigroup Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $12
- Why Is Nuvation Bio Stock Gaining Thursday?
- Nuvation Bio Says FDA Approves sNDA For IBTROZI, ROS1 Inhibitor For Treatment Of Locally Advanced Or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
- Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
- Citizens Reiterates Market Outperform on Nuvation Bio, Maintains $10 Price Target
Your note
Sign in to keep a note on NUVB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HANLEY DAVID C | Chief Technology Officer | Conversion of Exercise of derivative security | Nov 18, 2025 | 24,000 |
| HUNG DAVID T | Chief Executive Officer | Purchase | Jun 15, 2025 | 59,281,100 |
| LIU DONGFANG | Officer | Conversion of Exercise of derivative security | Apr 16, 2026 | 18,000 |
| MAKUNJE MOSES | Officer | Stock Award(Grant) | Feb 26, 2026 | 68,137 |
| MARKEL STACY | Officer | Conversion of Exercise of derivative security | Jun 22, 2026 | 32,591 |
| MASHAL ROBERT | Director | Purchase | Jun 8, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.88% | 52,230,295 | 248.36M | Jun 29, 2026 |
| Blackrock Inc. | 7.87% | 27,630,837 | 131.38M | Jun 29, 2026 |
| Decheng Capital LLC | 7.39% | 25,954,439 | 123.41M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.39% | 11,919,514 | 56.68M | Jun 29, 2026 |
| Omega Fund Management, Llc | 2.30% | 8,081,089 | 38.43M | Jun 29, 2026 |
| Laurion Capital Management, LP | 2.23% | 7,820,013 | 37.18M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 5.04% | 17,697,414 | 84.15M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.52% | 8,849,329 | 42.08M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.86% | 6,523,172 | 31.02M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1.42% | 4,985,277 | 23.70M | Aug 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 1.30% | 4,561,397 | 21.69M | Aug 30, 2026 |
| American Century Mutual Funds, Inc.-Small Cap Growth Fund | 0.98% | 3,423,823 | 16.28M | Jul 30, 2026 |